Aurinia Reports Q3 2026 Revenue of $83.7 Million, Raises Full-Year Guidance
Aurinia reported Q3 2026 revenue of $83.7M, up 14% YoY, and net income of $31.7M. Nine-month revenue rose 19% to $244.6M. The company raised its 2026 revenue guidance to $325M–$330M and narrowed net product sales outlook. Aurinia also initiated new clinical studies for LUPKYNIS and aritinercept.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift provide a fresh catalyst for the stock, likely prompting short‑term buying pressure.
Market read
New earnings and guidance data constitute primary disclosure for a micro‑cap biotech, offering a clear trading signal.
What to watch
Potential regulatory hurdles for LUPKYNIS and the success of the PRESERVE study could alter outlook.
Background
Aurinia is a biotech focused on lupus nephritis treatments, with LUPKYNIS already FDA‑approved and a Phase 4 PRESERVE study underway.
Ticker impact
Aurinia Pharmaceuticals reported Q3 2026 results and raised its full-year revenue guidance to $325M‑$330M.
likely upside as the market prices in the higher revenue outlook
Revenue grew 14% YoY and guidance was increased, a material new data point for a micro‑cap biotech.
Market effects
Boosts sentiment for the lupus‑treatment and broader biotech sector.
Limited to US biotech investors; no broader regional effect.
Minor global impact; primarily relevant to US‑listed biotech stocks.
Counterpoint
The guidance raise may already be priced in; risk of execution delays in clinical trials.
Key entities
- companyAurinia Pharmaceuticals Inc.
Biopharmaceutical company developing lupus nephritis therapies.
